文献速递消化道肿瘤放疗

直肠癌新辅助放化疗后手术时间与病理完全缓解的人群研究

Time to surgery and pathologic complete response after neoadjuvant chemoradiation in rectal cancer: A population study on 2094 patients.
PubMed 文献 · Clin Transl Radiat Oncol · 2017-05-17

该多中心回顾性队列研究纳入1997至2016年意大利21家放疗机构的2094例局部晚期直肠癌患者,按放化疗至全直肠系膜切除的时间间隔分组。总体病理完全缓解(pCR)率为22.3%,间隔6周内、7-12周、13周及以上组的pCR率分别为12.6%、23%和31.1%(p<0.001)。延长间隔至13周以上与pCR改善相关。

要点

  • 放化疗后手术间隔13周以上组pCR率达31.1%,高于6周内组的12.6%。
  • 多因素分析中,较长间隔是唯一与pCR相关的因素(p<0.001)。
  • 放疗剂量>5040 cGy和双药化疗与病理部分缓解率相关。

核心结论

  • 在人群水平上证实,延长放化疗至手术的间隔至13周以上可改善病理反应(pCR和病理部分缓解)。

研究设计与样本

  • 多中心回顾性队列研究,纳入意大利21家放疗机构的2094例局部晚期直肠癌患者。
  • 患者按放化疗至全直肠系膜切除的时间间隔分为3组:6周内300例、7-12周1598例、13周及以上196例。

主要发现

  • 总体pCR率为22.3%(468例)。
  • 6周内组pCR率为12.6%,7-12周组为23%,13周及以上组为31.1%(p<0.001)。
  • 7-12周组相对于6周内组的pCR相对风险为1.8,13周及以上组相对于7-12周组为1.3。
  • 13周及以上组相对于6周内组的pCR相对风险为2.4(p<0.01)。
  • 单因素分析中,临床III期(p<0.001)、放疗剂量>5040 cGy(p=0.002)和较长间隔(p<0.001)与pCR显著相关;多因素分析中较长间隔是唯一相关因素(p<0.001)。

关键数值与推荐

  • pCR率:6周内组12.6%,7-12周组23%,13周及以上组31.1%(p<0.001)。
  • pCR相对风险:7-12周组vs 6周内组为1.8;13周及以上组vs 7-12周组为1.3;13周及以上组vs 6周内组为2.4(p<0.01)。
  • 单因素分析中与pCR相关的因素:临床III期(p<0.001)、放疗剂量>5040 cGy(p=0.002)、较长间隔(p<0.001)。

临床怎么用

  • 对于局部晚期直肠癌患者,可考虑将放化疗至手术的间隔延长至13周以上以改善病理完全缓解。
  • 放疗剂量>5040 cGy和双药化疗可能与病理部分缓解率相关。

局限性

  • 回顾性研究设计可能存在选择偏倚。
  • 原文未报告各组基线特征差异、具体放化疗方案细节及长期生存结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To retrospectively evaluate the difference in terms of pathologic complete response (pCR) according to time elapsed between chemoradiation (CRT) and total mesorectal excision (TME) on a large unselected real-life dataset of locally advanced rectal cancer (LARC) patients. METHODS: A multicentre retrospective cohort study of LARC patients from 21 Italian Radiotherapy Institutions was performed. Patients were stratified into 3 different time intervals from CRT. The 1st group included 300 patients who underwent TME within 6 weeks, the 2nd 1598 patients (TME within 7-12 weeks) and the 3rd 196 patients (TME within 13 or more weeks after CRT), respectively. RESULTS: Data on 2094 LARC patients treated between 1997 and 2016 were considered suitable for analysis. Overall, 578 patients had stage II while 1516 had stage III histological proven invasive rectal adenocarcinoma. A CRT schedule of one agent (N = 1585) or 2-drugs (N = 509) was administered. Overall, pCR was 22.3% (N = 468 patients). The proportion of patients achieving pCR with respect to time interval was, as follows: 12.6% (1st group), 23% (2nd group) and 31.1% (3rd group) (p < 0.001), respectively. The pCR relative risk comparison of 2nd to 1st group was 1.8, while 3rd to 2nd group was 1.3. Moreover, between the 3rd and 1st group, a pCR relative risk of 2.4 (p < 0.01) was noted. At univariate analysis, clinical stage III (p < 0.001), radiotherapy dose >5040 cGy (p = 0.002) and longer interval (p < 0.001) were significantly correlated to pCR. The positive impact of interval (p < 0.001) was confirmed at multivariate analysis as the only correlated factor. CONCLUSION: We confirmed on a population-level that lengthening the interval (>13 weeks) from CRT to surgery improves the pathological response (pCR and pathologic partial response; pPR) in comparison to historic data. Furthermore, radiotherapy dose >5040 cGy and two drugs chemotherapy correlated with pPR rate.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Macchia G, Gambacorta MA, Masciocchi C, et al. Time to surgery and pathologic complete response after neoadjuvant chemoradiation in rectal cancer: A population study on 2094 patients. Clin Transl Radiat Oncol. 2017. PMID: 29594202. doi:10.1016/j.ctro.2017.04.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。